Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease

Kim, J S; Chung, Su Jin; Choi, Youngok; Cheon, Jae Hee; Kim, C W; Kim, S G; Jung, Hyun Chae; Song, In Sung

doi:10.1038/sj.bjc.6603708

Cited by 49 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The location of the lesion is one of the factors associated with efficacy. Kim et al (2007) have reported that in H. pylori-infected gastric MALT lymphoma patients, those with distal lesions had higher CR rates (92.5%) than those with proximal lesions (CR rate 65.5%). We also observed the same tendency in H. pylori-negative MALT lymphoma patients, among whom only the responders had antral lesions, but this tendency did not show statistical significance due to the limited number of patients.…”

Section: Discussionmentioning

confidence: 99%

Eradication Therapy Is Effective for <i>Helicobacter pylori</i>-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Asano

Iijima

Terai

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Mucosa-associated lymphoid tissue (MALT) lymphomas are extra-nodal B-cell lymphomas arising from MALT, and the most commonly affected organ is the stomach. Helicobacter pylori (H. pylori) eradication therapy with proton-pump inhibitors and antibiotics is the first-line therapy for H. pylori-positive gastric MALT lymphomas, but the effectiveness of the therapy for H. pylori-negative gastric MALT lymphomas remains controversial. Hence, we aimed to evaluate the effectiveness of this eradication therapy for H. pylorinegative MALT lymphomas. The H. pylori infection status of 158 gastric MALT lymphoma patients followed in our unit was judged by urea breath test, rapid urease test, histology of the biopsy specimen taken from the stomach during endocopy, and serum antibody against H. pylori. Seventeen patients that were negative for all four tests and did not have gastric mucosal atrophy were treated with antibiotic eradication therapy. The average age at diagnosis was 56.8 years old (range: 36-73 years), and the median follow-up period after H. pylori eradication in all 17 patients was 5.3 years (range: 0.3-12.7 years). Five patients (29.4%) achieved complete remission (CR) by eradication therapy alone. Comparison between the responding and non-responding patients revealed that the patients endoscopically diagnosed to have a single lesion of gastric MALT lymphoma were seen only in the responding group, whereas all non-responding patients had multiple lesions (P < 0.05). In conclusion, H. pylori eradication therapy achieved a favorable CR rate in H. pylori-negative gastric MALT lymphoma patients and could be considered as a first-line therapy, especially for patients with a single lesion.

show abstract

Section: Discussionmentioning

confidence: 99%

Eradication Therapy Is Effective for <i>Helicobacter pylori</i>-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Asano

Iijima

Terai

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Of these, 29 trials were finally included , whilst the remaining 12 studies were excluded due to lack of either treatment option chosen or treatment efficacy following H. pylori eradication therapy failure [38][39][40][41][42][43][44][45][46][47][48][49]. Among the 29 trials included in this pooled-data analysis, the study design was prospective in 21 series and retrospective in the remaining eight series.…”

Section: Descriptive Analysismentioning

confidence: 99%

Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy

et al. 2009

View full text Add to dashboard Cite

The most favourable therapeutic strategy for gastric MALT-lymphoma not responding to Helicobacter pylori eradication still remains unclear, neither official guidelines nor randomised studies being available. We therefore performed a systematic review of the literature to evaluate the efficacy of different therapeutic approaches in these patients. Data regarding 315 patients were valuable, and lymphoma remission following the first therapeutic attempt was achieved in 90.1% cases. The most used therapy was radiotherapy (112 patients), followed by surgery (80 patients) and chemotherapy (68 patients), whilst a combination therapy was less frequent. Radiotherapy achieved a higher remission rate as compared to chemotherapy (97.3 vs. 85.3%; P = 0.007), being similar to surgery (97.3 vs. 92.5%; P = 0.2). No difference emerged when comparing lymphoma remission rate achieved by a single therapy with that of combined treatments (89.6 vs. 96.4%; P = 0.6). This is the first pooled-data analysis assessing the efficacy of different oncologic therapeutic approaches to treat gastric MALT-lymphoma unresponsive to H. pylori eradication. Radiotherapy seems to be the most suitable treatment in these patients.

show abstract

“…In recent years, several large‐scale studies have investigated the efficacy of H. pylori eradication therapy against gastric MALT lymphoma. Among previous studies with around 100 subjects, CR was achieved in 80% (96/120) in a German multicenter prospective study,17 94% (85/90) in a Korean prospective study,18 85% (84/99) in a Korean single‐center prospective study,19 74% (146/196) in a German single‐center retrospective study,20 76% (78/102) in a joint Swiss‐Italian retrospective study,21 77% (323/420) in a Japanese retrospective study,15 and 83% (78/94) in a Portuguese single‐center retrospective study 22. However, CR criteria varied among those studies.…”

Section: Discussionmentioning

confidence: 84%

“…Relapse of gastric MALT lymphoma was recorded in 64 of the 852 patients who achieved CR (7.5%), and treatment failure (relapse, PD, and/or non‐CR at ≥6 months after successful H. pylori eradication) was observed in 144 of all 1055 patients (13.6%). Table 3 summarizes 8 prospective studies,17, 18, 19, 30, 31, 32, 33 including the present investigation, of 47‐120 patients. The present study (n = 97) represents the third largest among these prospective studies.…”

Section: Discussionmentioning

confidence: 99%

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

et al. 2018

View full text Add to dashboard Cite

Background Helicobacter pylori eradication therapy was approved in Japan for the first‐line, standard treatment of H. pylori‐positive gastric mucosa‐associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small‐scale single‐center studies have been reported, a prospective, large‐scale, nationwide, multicenter study has not been reported from Japan.Materials and MethodsWe conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole‐based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice‐based clinical trial. A total of 108 H. pylori‐positive patients with stage I/II 1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS).Results CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0‐44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4‐53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow‐up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma.ConclusionsRabeprazole‐based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice‐based, multicenter study.

show abstract

Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease

Cited by 49 publications

References 19 publications

Eradication Therapy Is Effective for <i>Helicobacter pylori</i>-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Eradication Therapy Is Effective for <i>Helicobacter pylori</i>-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

Contact Info

Product

Resources

About